biostudies-literatureMetzger-Filho ONCI NIH HHS3083-90https://www.ebi.ac.uk/biostudies/studies/S-EPMC3753700biostudies-literatureUnknown31(25)<h4>Purpose</h4>To retrospectively evaluate the pattern of recurrence and outcome of node-negative breast cancer (BC) according to major subtypes.<h4>Patients and methods</h4>In all, 1,951 patients with node-negative, early-stage BC randomly assigned in International Breast Cancer Study Group Trials VIII and IX with centrally reviewed pathology data were included. BC subtypes were defined as triple negative (TN; n = 310), human epidermal growth factor receptor 2 (HER2) positive (n = 369), and hormone receptor positive with high (luminal B-like [LB-like]; n = 763) or low (luminal A-like [LA-like]; n = 509) proliferative activity by Ki-67 labeling index. BC-free interval (BCFI) events were invasive BC recurrence in local, contralateral breast, nodal, bone, or visceral sites. Time to first siJournal of clinical oncology : official journal of the American Society of Clinical OncologyPatterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.PMC3753700U24 CA075362Viale GGelber RDGoldhirsch ASnyder RDPrice KNCardoso FCoates ASCrivellari DCastiglione-Gertsch MSun ZMetzger-Filho OfalsePatterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.<h4>Purpose</h4>To retrospectively evaluate the pattern of recurrence and outcome of node-negative breast cancer (BC) according to major subtypes.<h4>Patients and methods</h4>In all, 1,951 patients with node-negative, early-stage BC randomly assigned in International Breast Cancer Study Group Trials VIII and IX with centrally reviewed pathology data were included. BC subtypes were defined as triple negative (TN; n = 310), human epidermal growth factor receptor 2 (HER2) positive (n = 369), and hormone receptor positive with high (luminal B-like [LB-like]; n = 763) or low (luminal A-like [LA-like]; n = 509) proliferative activity by Ki-67 labeling index. BC-free interval (BCFI) events were invasive BC recurrence in local, contralateral breast, nodal, bone, or visceral sites. Time to first si2013-01-01T00:00:00Z2013 Sep2025-04-04T22:07:50.405Z2019-03-27T01:15:06ZS-EPMC37537002389795410.1200/jco.2012.46.157410.1200/JCO.2012.46.1574